

Growing Up and Leaving Home

Transitioning 21st Century Computational Toxicology and New Approach Methods into Application





11th World Congress on Alternatives and Animal Use in the Life Sciences

August 23, 2021

Rusty Thomas
Director
Center for Computational Toxicology and Exposure


The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the U.S. EPA

The 3Rs are Over 60, but the New Generation of Alternative Approaches are Relatively Young...




Despite the Range in Ages, the Underlying Drivers Continue to Be the Same...

Number of Substances




Amount of Data

% of Non-Confidential, Active TSCA Inventory with Repeat Dose Toxicity Studies




*Data from ToxValDB (Dec 2019)


Reliability/Relevance



Time




Economics



Ethical and Societal Considerations



Five Keys to Growing Up and Leaving Home for Computational Toxicology and NAMs



- Know where you want to go and how to get there
- Set expectations for success
- Continue developing and improving the science
- Start small and build on successes
- Communicate, communicate, communicate


Knowing Where To Go and How to Get There Requires a Plan...



Know Where You
Want to Go...



Focused on Agency-wide action



Focused on TSCA




Focused on research

The Plans Contain Similar Strategic Directions and an Operational Blueprint




Know Where You
Want to Go...




Primary Objectives

- Evaluate Regulatory Flexibility
- Develop Baselines and Metrics
- Establish Scientific Confidence and Demonstrate Application
- Develop NAMs to Address Information Gaps
- Engage and Communicate with Stakeholders




Core Components

- Identifying, Developing, and Integrating NAMs
- Building Confidence that NAMs are Scientifically Reliable and Relevant
- Implementing the Reliable and Relevant NAMs



Setting Expectations for NAMs Requires Data

Evaluating LEL/LOAEL Variability in Traditional Toxicity Studies by Mining Legacy Data for ~1,200 Chemicals



Using an RMSE=0.59, the 95% Prediction Interval of an LEL/LOAEL is +/- 10-fold (e.g., 1 mg/kg/day, 0.07 – 14)

Pham et al., Comp Toxicol., 2020

Evaluating Target Organ Variability in Traditional Toxicity Studies by Mining Legacy Data for ~1,200 Chemicals

Organ	Species	Repeated negative	Mixed effects	Repeated positive	% Concordance
Liver	dog	20	26	46	71.7
	mouse	30	40	69	71.2
	rat	42	71	132	71.0
Kidney	dog	49	33	10	64.1
	mouse	61	51	27	63.3
	rat	60	105	80	57.1
Spleen	dog	64	21	7	77.2
	mouse	93	31	15	77.7
	rat	132	84	29	65.7
Testes	dog	65	20	7	78.3
	mouse	110	20	9	85.6
	rat	135	87	23	64.5
Adrenal gland	dog	76	12	4	87.0
	mouse	109	23	7	83.5
	rat	142	83	20	66.1

Paul-Friedman, Unpublished

Literature Review and Expert Committee Report to Inform Expectations for NAMs

The National Academies of


SCIENCES
ENGINEERING
MEDICINE

SEARCH Q

About Us Events Our Work Publications Topics Engagement Opportunities

Variability and Relevance of Current Laboratory Mammalian Toxicity Tests and Expectations for New Approach Methods (NAMs) for use in Human Health Risk Assessment

SHARE f t in x



- About
- Description
- Sponsors
- Contact

Animal testing is often used to evaluate the potential risks, uses, and environmental impacts of chemicals. New Approach Methodologies (NAMs) are technologies and approaches that can potentially provide the same hazard and risk assessment information without the use of animal testing. To further establish scientific confidence in these approaches, this study will review the variability and relevance of existing mammalian toxicity tests, specifically when it comes to human health risk assessment. The goal of this study is to to set data-driven and science-based expectations for NAMs based on the variability and relevance of the traditional toxicity testing models.



Provide feedback on this project

High-Content Technologies are Being Applied to Increase Biological Coverage

3

Continue Improving
the Science...

Broad-Based Testing Using High-Content Technologies




J. Harrill *et al.*, Unpublished

Improving Organotypic Culture Models to Translate Molecular Events into Tissue Effects




Continue Improving
the Science...

Normal Human
Thyroid Gland



Harvest Follicle
Fragments



Attachment and
Outgrowth of Cells


2D Cell Expansion









2D Monolayer
Culture



3D Sandwich
Culture





Blue, Hoechst 33342 /DNA
Green, Phalloidin/Actin





Deisenroth *et al.*, *Toxicol Sci*, 2020


Toxicokinetic NAMs for Extrapolating *In Vitro* Concentrations to Administered Doses



Experimental Models for Bioavailability



Generic PBTK Model for Inhalation Exposure



Rotroff *et al.*, *Tox Sci.*, 2010
Wetmore *et al.*, *Tox Sci.*, 2012
Wetmore *et al.*, *Tox Sci.*, 2015
Wambaugh *et al.*, *Tox Sci.*, 2018
Wambaugh *et al.*, *Tox Sci.*, 2019
Linakis *et al.*, *J Expo Sci Environ Epidemiol.* 2020

Case Study to Demonstrate Application of NAMs To Screening Level Assessments



Start Small and Build on Successes...

SOT Society of Toxicology
academic.oup.com/toxsci

TOXICOLOGICAL SCIENCES, 2019, 1–24
doi:10.1093/toxsci/kfz201
Advance Access Publication Date: September 18, 2019
Research Article

Utility of *In Vitro* Bioactivity as a Lower Bound Estimate of *In Vivo* Adverse Effect Levels and in Risk-Based Prioritization

Katie Paul Friedman ,^{*,1} Matthew Gagne,[†] Lit-Hsin Loo,[‡] Panagiotis Karamertzanis,[§] Tatiana Netzeva,[§] Tomasz Sobanski,[§] Jill A. Franzosa,[¶] Ann M. Richard,^{*} Ryan R. Lougee,^{*,||} Andrea Gissi,[§] Jia-Ying Joey Lee,[‡] Michelle Angrish,^{||} Jean Lou Dorne,^{|||} Stiven Foster,[#] Kathleen Raffaele,[#] Tina Bahadori,^{||} Maureen R. Gwinn,^{*} Jason Lambert,^{*} Maurice Whelan,^{**} Mike Rasenberg,[§] Tara Barton-Maclaren,[†] and Russell S. Thomas

^{*}National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, 27711; [†]Healthy Environments and Consumer Safety Branch, Health Canada, Government of Canada, Ottawa, Ontario, Canada, K1A0K9; [‡]Innovations in Food and Chemical Safety Programme and Bioinformatics Institute, Agency for Science, Technology and Research, Singapore, 138671, Singapore; [§]Computational Assessment Unit, European Chemicals Agency, European Chemicals Agency Annankatu 18, P.O. Box 400, FI-00021 Helsinki, Uusimaa, Finland; [¶]National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, 27711; ^{||}Oak Ridge Institute for Science and Education, U.S. Department of Energy, Oak Ridge, TN 37831, USA; ^{|||}National Center for Environmental Assessment, Office of Research and Development, US Environmental Protection Agency, Washington, DC, 20004 and Research Triangle Park, NC 27711; ^{||}Scientific Committee and Emerging Risks Unit Department of Risk Assessment and Scientific Assistance, Via Carlo Magno 1A, 43126 Parma, Italy; [#]Office of Land and Emergency Management, U.S. Environmental Protection Agency, Washington, DC, 20004; and ^{**}European Commission, Joint Research Centre (JRC), Via Enrico Fermi, 2749, I - 21027 Ispra, Italy


^{*}To whom correspondence should be addressed at 109 T.W. Alexander Drive, Mail Drop D143-02, Research Triangle Park, NC 27711. Fax: (919) 541-1196. E-mail: paul.friedman.katie@epa.gov

Disclaimer: The United States Environmental Protection Agency (U.S. EPA) through its Office of Research and Development has subjected this article to Agency administrative review and approved it for publication. Mention of trade names or commercial products does not constitute endorsement for use. The views expressed in this article are those of the authors and do not necessarily represent the views or policies of ATSDR, U.S. EPA, EFSA, ECHA, Health Canada, or the JRC.

ABSTRACT

Use of high-throughput, *in vitro* bioactivity data in setting a point-of-departure (POD) has the potential to accelerate the pace of human health safety evaluation by informing screening-level assessments. The primary objective of this work was to compare PODs based on high-throughput predictions of bioactivity, exposure predictions, and traditional hazard information for 448 chemicals. PODs derived from new approach methodologies (NAMs) were obtained for this comparison using the 50th (POD_{NAM, 50}) and the 95th (POD_{NAM, 95}) percentile credible interval estimates for the steady-state plasma

Published by Oxford University Press on behalf of the Society of Toxicology 2019.
This work is written by US Government employees and is in the public domain in the US.




Goal: Determine whether *in vitro* bioactivity from broad-based NAMs can be used as a conservative point-of-departure and when compared with exposure estimates serve to prioritize chemicals for future study or as lower tier risk assessment.

Paul-Friedman et al., 2020

Case Study to Demonstrate Application of NAMs To Screening Level Assessments



Start Small and Build
on Successes...



For ~89% of the
chemicals, POD_{NAM}
was conservative.
(~100-fold on
average), but less
conservative than
a TTC

Chemicals where
 POD_{NAM} was not
conservative
enriched in
OPs/carbamates

Building on the Concept for Regulatory and Product Development Decisions



Start Small and Build
on Successes...

**A Proof-of-Concept Study
Integrating Publicly Available
Information to Screen
Candidates for Chemical
Prioritization under TSCA**

EPA
EPA/600/R-21-106

Science Approach Document

Bioactivity Exposure Ratio: Application in Priority Setting and Risk Assessment

Health Canada

March 2021

Computational Toxicology 7 (2018) 20–26

Contents lists available at ScienceDirect

Computational Toxicology

journal homepage: www.elsevier.com/locate/comtox

Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients

Matthew Dent^{a,*}, Renata Teixeira Amaral^b, Pedro Amores Da Silva^b, Jay Ansell^c, Fanny Boislevé^d, Masato Hatao^e, Akihiko Hirose^f, Yutaka Kasai^g, Petra Kern^h, Reinhard Kreilingⁱ, Stanley Milstein^j, Beta Montemayor^k, Julcemara Oliveira^l, Andrea Richarz^m, Rob Taalmanⁿ, Eric Vaillancourt^o, Rajeshwar Verma^a, Nashira Vieira O'Reilly Cabral Posada^p, Craig Weiss^q, Hajime Kojima^r

^a Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK
^b ABHPEC – Association of the Cosmetics, Toiletry and Fragrance Industry (ABHPEC), Av. Paulista, 1313 Cordeiro César, São Paulo, SP 01311-000, Brazil
^c US Personal Care Products Council (PCPC), 1620 I St. NW, Suite 1200, Washington, D.C. 20006, USA
^d Johnson & Johnson Sterile Ocular Products, Domaine de Maignemont, CS 10615, F-27106 VAL D'ISÈRE Cedex, France
^e Japan Cosmetic Industry Association (KJIA), Metro City Kamayacho 6F, 5-1-5, Toranomon, Minato-ku, Tokyo 105-0001 Japan
^f National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, 158-8501 Tokyo, Japan
^g Kao Corporation, External Relations & Government Affairs 2-1-3, Bunkyo, Saitama-Ku, Tokyo 113-8501 Japan
^h Procter and Gamble Services Company NV, Temeldeen 100, 1-1823 Sprangbuisen, Belgium
ⁱ Clariant Products (DE) GmbH, Global Toxicology and Ecotoxicology, Am Unten-Park 1, 65843 Sulzbach, Germany
^j US Food and Drug Administration (US FDA), Office of Cosmetics and Colors (OCCAC), Center for Food Safety and Applied Nutrition (CFSAN), 5001 Campus Drive, College Park, MD 20740, USA
^k Cosmetics Alliance Canada, 420 Britannia Road East Suite 102, Mississauga, ON L4T 3L5, Canada
^l Brazilian Health Regulatory Agency (ANVISA), Gerência de Produtos de Higiene, Perfumaria, Cosméticos e Saneantes, SA Trêcho 5, Ite 200, Área Especial 57 – CEP 71205-000, Brazil
^m European Commission, Joint Research Centre (JRC), Directorate for Health, Consumers and Reference Materials, Chemical Safety and Alternative Methods Unit, Via E. Fermi 27/49, 21027 Ispra, VA, Italy
ⁿ Cosmetics Europe, Avenue Hermann Debrée 40, 1160 Auderghem, Belgium
^o Health Canada (HC), Consumer Product Safety Directorate, Healthy Environments and Consumer Safety Branch, 269 Laurier Ave. W., Ottawa, ON K1A 0K9, Canada
^p Independent Cosmetic Manufacturing and Distributors (ICMAD), 21925 Field Parkway, Suite 2015, Deer Park, IL 60010, USA
^q Corresponding author.
E-mail address: matthew.dent@unilever.com (M. Dent).

<https://doi.org/10.1016/j.comtox.2018.06.001>
Received 18 April 2018; Received in revised form 14 June 2018; Accepted 18 June 2018
Available online 20 June 2018
2468-1113/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Case Study on Application of NAMs for Developmental Neurotoxicity




Start Small and Build
on Successes...

Agency Issue Paper:

Use of New Approach Methodologies to Derive
Extrapolation Factors and Evaluate Developmental
Neurotoxicity for Human Health Risk Assessment

July 2020




Key Question: How do NAMs for key cellular events and processes relevant to developmental neurotoxicity compare to *in vivo* AChE changes in rats on an administered dose basis for organophosphate pesticides (i.e., is AChE protective of potential DNT effects)?

Case Study on Application of NAMs for Developmental Neurotoxicity



Start Small and Build
on Successes...



Administered dose equivalents for NAMs relevant to developmental neurotoxicity are general higher or in some cases approaching the doses associated with significant *in vivo* changes in AChE activity.

Communicate and Share the Results With the Broader Community



Communicate,
Communicate...

Tailored Training for Specific
User Groups



Public Websites with Consolidated
Information on NAMs

Scientific Conferences and Webinars

Data Dashboards and
Decision Support Tools



<https://www.epa.gov/nam>



<https://comptox.epa.gov/dashboard>

Take Home Messages...

1

Know Where You
Want to Go...

2

Set Expectations for
Success...

3

Continue Improving
the Science...

4

Start Small and Build
on Successes...

5

Communicate,
Communicate...



Acknowledgements

Center for Computational Toxicology and Exposure (CCTE) Staff

Tox21 Colleagues:

NTP
FDA
NCATS

EPA Colleagues:

CEMM
CPHEA
CESER
OCSP

Collaborative Partners:

Unilever
A*STAR
ECHA
EFSA
Health Canada



Research Triangle Park, NC



Cincinnati, OH



Duluth, MN



Washington, DC



Athens, GA



Gulf Breeze, FL